World's first-of-its-kind novel oral cancer detection kit: This small-cap pharma company signs agreement with Kalinga Institute of Technology!

World's first-of-its-kind novel oral cancer detection kit: This small-cap pharma company signs agreement with Kalinga Institute of Technology!

Kiran Shroff
/ Categories: Trending, Mindshare

The global cancer market is estimated at USD 21.5 billion.

Supriya Lifescience Ltd, the Mumbai-based and one of the prominent specialized active pharmaceutical ingredients (API) manufacturing company, has collaborated with Kalinga Institute of Industrial Technology (KIIT), Bhubaneswar, to develop India’s first-of-its-kind novel oral cancer detection kit named Quickblue Oral Kit.

This oral cancer detection kit is designed to detect oral cancer cost-effectively and efficiently. This kit seamlessly detects oral cancer and could potentially reduce the need for extensive preclinical and clinical trials. The company has also filed for the patent of the Quickblue oral kit. This product is not only a cheaper option but also found very sensitive detector. The global cancer market is estimated at USD 21.5 billion and the company is expecting to create a 1-2 per cent market share.

Supriya Lifescience is a company that makes active pharmaceutical ingredients (APIs). As of March 31, 2021, the company produces 38 different APIs for a variety of therapeutic areas, including antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatics, and anti-allergies.

Supriya Lifescience has a market cap of Rs 1,923 crore and has a good return on equity (ROE) track record: 3 Years ROE 27.9 per cent. The company reported positive numbers in its Quarterly Results and annual results. As of September 2023, the promoters own 68.3 per cent of the company, followed by foreign institutional investors (FIIs) at 5.35 per cent, domestic institutional investors (DIIs) at 7.17 per cent, and the public at 19.18 per cent.

On Friday, shares of Supriya Lifescience plunged 3.12 per cent to Rs 238.95 per share with an intraday high of Rs 247.55 and an intraday low of Rs 237.

The stock is up over 40 per cent from its 52-week low of Rs 170.05 per share. Investors should keep an eye on this Small-Cap pharma stock

DSIJ’s 'Tiny Treasure' service recommends researched small-cap stocks with Inherent Growth Potential. If this interests you, do download the service details here.

Previous Article Sanjiv Shah’s and Mukul Agrawal’s portfolio multibagger stock with USD 2 million capex; Board likely to announce stock split & dividend!
Next Article Rs 17,643 crore order book: This multibagger power company signs 12.5 MW PDA with Supreme Petrochem Limited!
Rate this article:
3.6

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR